ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC (BDRX)

0.981
0.001
(0.10%)
Closed June 16 4:00PM
0.9999
0.0189
(1.93%)
After Hours: 7:40PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.9999
Bid
0.93
Ask
1.25
Volume
83,687
0.9611 Day's Range 0.9999
0.00 52 Week Range 0.00
Market Cap
Previous Close
0.98
Open
0.9775
Last Trade
9
@
0.976
Last Trade Time
Financial Volume
$ 82,232
VWAP
0.98261
Average Volume (3m)
-
Shares Outstanding
-
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC is a United Kingdom-based drug delivery technology company. The Company is focused on improving the bio-delivery and bio-distribution of medicines. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. Biodexa Pharmaceuticals Q-Sphera technolo... Biodexa Pharmaceuticals PLC is a United Kingdom-based drug delivery technology company. The Company is focused on improving the bio-delivery and bio-distribution of medicines. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. Biodexa Pharmaceuticals Q-Sphera technology focuses on long acting injectables using proprietary 3D printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. It has a pipeline of approximately eight earlier stage programs, MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma), MTX110 (Glioblastoma), MTX114 (Psoriasis), MTD211 (Schizophrenia, MDD) and others. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Cardiff, Gbr
Founded
1970
Biodexa Pharmaceuticals PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BDRX. The last closing price for Biodexa Pharmaceuticals was $0.98. Over the last year, Biodexa Pharmaceuticals shares have traded in a share price range of $ 0.00 to $ 0.00.

Biodexa Pharmaceuticals currently has 0 shares outstanding.

BDRX Latest News

Results of Annual General Meeting

13 June 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), an acquisition-focused clinical stage...

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona

June 10, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious...

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

May 22, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations...

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

May 21, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous...

Posting of Annual Report & Notice of AGM - Total Voting Rights

May 15, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Total Voting Rights Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical...

Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting

April 30, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be...

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis...

Preliminary Results for the Year Ended 31 December 2023

19 April 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2023 Biodexa...

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update Median Overall...

Biotech Shares Bid Up Premarket Following 9.9% Institutional Stake Disclosure

With biotech stocks finding trememdous success in recent months, it’s no wonder why everyone wants to get in on the action, including institutional investors. After To read the full story on...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.99M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.29k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.34M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.83M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.77M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.46M

BDRX Discussion

View Posts
The Night Stalker The Night Stalker 3 weeks ago
when
👍️0
The Night Stalker The Night Stalker 3 weeks ago
when
👍️0
The Night Stalker The Night Stalker 3 weeks ago
on sale
👍️0
glenn1919 glenn1919 4 weeks ago
BDRX...................................https://stockcharts.com/h-sc/ui?s=BDRX&p=W&b=5&g=0&id=p86431144783
👍️0
BurgerKing82 BurgerKing82 4 weeks ago
Looking good
👍️0
Zardiw Zardiw 2 months ago
Is that why we have No FAP November?

Z
👍️0
Zardiw Zardiw 2 months ago
$BDRX Chart from #DDAmanda - #1 Stock Screener :

Push a Button. Find Winners Early. Scans are preset but can be modified. :



Z
👍️0
glenn1919 glenn1919 2 months ago
BDRX..................................................https://stockcharts.com/h-sc/ui?s=BDRX&p=W&b=5&g=0&id=p86431144783
👍️0
Invest-in-America Invest-in-America 2 months ago
BDRX: Heck, last time I saw an iHub board THIS quiet, was on the AAPL board when Steve Jobs croaked!!

👍️0
Invest-in-America Invest-in-America 2 months ago
SONG BREAK:

👍️0
KOmani KOmani 2 months ago
Well, looks to have caught a bid.

We shall see if $2 is still going to hit.

The financing from December was at $2.00 per share. (Per ADS share).

I only chose the $2 mark because that is were they did an offering ... not because I thought it deserved to hit the next dollar mark.
👍️0
KOmani KOmani 2 months ago
Looks like exchange ratio is 1:400

Meaning 3 million shares.
👍️0
subslover subslover 2 months ago
Why? The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2023 was: 1,189,577,722 Ordinary Shares
👍️0
KOmani KOmani 2 months ago
Hmmm... this sounds like fantastic news.

So, why is is still below $2?

Explain to me like I buy stocks to generate income? (ELI0)
👍️0
TheFinalCD TheFinalCD 2 months ago
FAP is a substantially genetic orphan disease for which there are no approved therapeutic options; the current standard of care is surveillance and surgery
Phase 3 FAP program is supported by a $17 million grant awarded from the Cancer Prevention and Research Institute of Texas (“CPRIT”) in a competitive process
Phase 2 results in FAP to be presented at two leading scientific conferences in Q2 ‘24
Ongoing Phase 2 study in Non-muscle Invasive Bladder Cancer expected to read-out in Q2 ‘25
Phase 2 study in NMI Bladder Cancer supported by $3 million grant from National Cancer Institute, part of the National Institutes of Health
$BDRX
👍️0
subslover subslover 2 months ago
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
April 26, 2024

Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the
Treatment of Familial Adenomatous Polyposis (FAP)

Worldwide rights come with $17 million in non-dilutive grant funding for Pivotal Phase 3 trial in FAP

An estimated 100,000 in U.S. and Europe are afflicted with FAP, precancerous polyps that typically lead to surgical removal of the colon and/or rectum

In FAP, eRapa holds the potential of delaying or preventing surgical intervention

Multiple opportunities seen in other indications, including bladder and prostate cancers

FAP is a substantially genetic orphan disease for which there are no approved therapeutic options; the current standard of care is surveillance and surgery
Phase 3 FAP program is supported by a $17 million grant awarded from the Cancer Prevention and Research Institute of Texas (“CPRIT”) in a competitive process
Phase 2 results in FAP to be presented at two leading scientific conferences in Q2 ‘24
Ongoing Phase 2 study in Non-muscle Invasive Bladder Cancer expected to read-out in Q2 ‘25
Phase 2 study in NMI Bladder Cancer supported by $3 million grant from National Cancer Institute, part of the National Institutes of Health
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced it entered into a definitive agreement with Rapamycin Holdings Inc. (d/b/a Emtora Biosciences) (“Emtora”) for the rights to eRapa under an exclusive, worldwide license (with the ability to grant sublicenses) to develop, manufacture, commercialize and otherwise advance the clinical potential of eRapa.

Stephen Stamp, CEO and CFO of Biodexa said, “Acquiring a Phase 3 ready asset, particularly one supported by $17 million of non-dilutive grant funding, significantly advances Biodexa’s oncology pipeline and adds numerous valuation catalysts for our stakeholders. We are delighted to be working with the Emtora team which has excelled in bringing eRapa close to the end of Phase 2 in Non-muscle Invasive Bladder Cancer and to the beginning of a Phase 3 trial in FAP, a devastating disease for which there is currently no approved pharmacological agent for altering its progression. Left untreated, it almost always leads to incredibly invasive surgery and a major deterioration in the quality of life.”

Stephen Dufilho, Executive Chairman of Emtora added, “The transaction with Biodexa is the culmination of a decade-long effort to advance our potentially game-changing eRapa to a registrational Phase 3 trial - and ultimately to patients in need. Our story began in San Antonio – where eRapa was originally invented at the University of Texas and funded in part by grants from the Cancer Prevention Research Institute of Texas. We thank the scientists, clinicians, investors and biotech executives that supported our efforts to reach this important milestone. We look forward to working with the Biodexa team as we embark upon this next chapter.”

About eRapa
eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis1. Rapamycin is approved in the US for organ rejection in renal transplantation as Rapamune®(Pfizer). Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to address the poor bioavailability, variable pharmacokinetics and toxicity generally associated with the currently available forms of rapamycin. eRapa is protected by a number of issued patents which extend through 2035, with other pending applications potentially providing further protection beyond 2035.

eRapa in FAP
FAP is characterized as a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option for treating FAP patients, for whom active surveillance and surgical resection of the colon and/or rectum remain the standard of care. If untreated, FAP typically leads to cancer of the colon and/or rectum. There is a significant hereditary component to FAP with a reported incidence of one in 5,000 to 10,000 in the US2 and one in 11,300 to 37,600 in Europe3. eRapa has received Orphan Designation in the US with plans to seek such designation in Europe. Importantly, mTOR has been shown to be over-expressed in FAP polyps – thereby underscoring the rationale for using a potent and safe mTOR inhibitor like eRapa to treat FAP.

Emtora is currently completing an open-label, multi-center Phase 2 study in 30 patients with confirmed FAP with the primary endpoints of safety and tolerability, and percentage change in polyp burden after six months of treatment with eRapa. The Phase 2 study was partially funded by a $3.0 million grant from CPRIT.
👍️0
TheFinalCD TheFinalCD 2 months ago
https://twitter.com/search?q=%24bdrx&src=typed_query&f=top

https://www.globenewswire.com/news-release/2024/04/26/2870466/0/en/Biodexa-Enters-Into-Exclusive-License-to-eRapa-a-Phase-3-Ready-Asset-for-the-Treatment-of-Familial-Adenomatous-Polyposis-FAP.html
👍️0
Monksdream Monksdream 2 months ago
There will be another price spike in the chart
👍️0
Awl416 Awl416 2 months ago
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
👍️0
Monksdream Monksdream 2 months ago
BDRX new 52 lo
👍️0
Zardiw Zardiw 3 months ago
$BDRX Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z
👍️0
da_stock_analyst da_stock_analyst 3 months ago
#BDRX 🔥 prepare for next week run! $bdrx
👍️0
glenn1919 glenn1919 3 months ago
BDRX.............................................https://stockcharts.com/h-sc/ui?s=BDRX&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
BDRX...HERE COMES 2.13
👍️0
Awl416 Awl416 3 months ago
Pop
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
BDRX...2.13 COMING IN
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
BDRX...DO WE SEE THAT 200 DAY @ 2.13
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
TRIMMING ABOVE THE 50
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
BDRX..BREAKING THE 50 DAY
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
BDRX..HERE WE GO!!!
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
BDRX...BEST PRE MARKET PLAY...MY AI SCANNER PICKS THE RIGHT ONES!!!
👍️0
Invest-in-America Invest-in-America 3 months ago
BDRX: Had some rather impressive CANCER news --- & vs. really aggressive Cancers.
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
BDRX...PRE TO OPEN PLAY!
👍️0
Monksdream Monksdream 3 months ago
BDRX under $2
👍️0
Monksdream Monksdream 4 months ago
BDRX new 52 week low
👍️0
knrorrel knrorrel 4 months ago
Yesterday after hours, shortly before the end, many buyers came in and bought this stock up to $1.89
👍️ 1
knrorrel knrorrel 4 months ago
Could you imagine that today, before the trading session, it would be so relaxed and easily over 4 dollars ?

👍️ 1
knrorrel knrorrel 4 months ago
ah up ?
👍️0
Stijn Stijn 4 months ago
Up again, let's see where it goes from here!
👍️0
TradeSmart.ai TradeSmart.ai 4 months ago
Yes this stock is trash tbh
👍️0
knrorrel knrorrel 4 months ago
I'M DEFINITELY OUT NOW AND THE STOCK IS SHIT AND STILL LANDS IN THE RED ZONE AND I THOUGHT IT WOULD JUMP BACK UP AT THE OPENING OF THE STOCK MARKET AND RUN OVER FOUR DOLLARS LIKE PRE-MARKET BUT YOU CAN FORGET THAT WITH THIS CRAP


👍️0
knrorrel knrorrel 4 months ago
Now seems to be the bottom (1.83) and $BDRX could run higher from here.

👍️0
TradeSmart.ai TradeSmart.ai 4 months ago
Hopefully you guys banked on that premarket pop weeeeee $BDRX
👍️0
ipo_dude ipo_dude 4 months ago
🤷🏿‍♂️🐒
👍️0
ipo_dude ipo_dude 4 months ago
This POS
👍️0
knrorrel knrorrel 4 months ago
$4 already and great Dip now and how high can $BDRX running today ?
👍️0
knrorrel knrorrel 4 months ago
IS THATS THE NEXT 1000% RUNNER ?
👍️0
declaes declaes 4 months ago
4 dollar printing... 😴
👍️0
subslover subslover 4 months ago
$BDRX = a very pretty early riser :)
👍️0
declaes declaes 4 months ago
Well this is a nice way to wake up this morning! 😀
👍️0

Your Recent History

Delayed Upgrade Clock